Retargeting Vesicular Stomatitis Virus Using Measles Virus Envelope Glycoproteins
- 1 May 2012
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 23 (5), 484-491
- https://doi.org/10.1089/hum.2011.146
Abstract
Oncolytic vesicular stomatitis virus (VSV) has potent antitumor activity, but infects a broad range of cell types. Here, we used the measles virus (MV) hemagglutinin (H) and fusion (F) envelope glycoproteins to redirect VSV entry and infection specifically to tumor-associated receptors. Replication-defective VSV, deleted of its glycoprotein gene (VSVΔG), was pseudotyped with MV-F and MV-H displaying single-chain antibodies (scFv) specific for epidermal growth factor receptor (EGFR), folate receptor (FR), or prostate membrane-specific antigen (PSMA). Viral titers were ∼105 PFU/ml, but could be concentrated to 107 PFU/ml. Immunoblotting confirmed incorporation of the MV-H-scFv and MV-F into functional VSV virions. Although VSV-G was able to infect all tumor cell lines tested, the retargeted VSV infected only cells that expressed the targeted receptor. In vivo specificities of the EGFR-, FR-, and PSMA-retargeted VSV were assessed by intratumoral injection into human tumor xenografts. Analysis of green fluorescent protein reporter gene expression indicated that VSV infection was restricted to receptor-positive tumors. In summary, we have demonstrated for the first time that VSV can be efficiently retargeted to different cellular receptors using the measles display technology, yielding retargeted VSV vectors that are highly specific for tumors that express the relevant receptor.Keywords
This publication has 39 references indexed in Scilit:
- Pseudotyping Vesicular Stomatitis Virus with Lymphocytic Choriomeningitis Virus Glycoproteins Enhances Infectivity for Glioma Cells and Minimizes NeurotropismJournal of Virology, 2011
- Use of attenuated paramyxoviruses for cancer therapyExpert Review of Vaccines, 2010
- Antibody-targeted cell fusionNature Biotechnology, 2004
- Defective translational control facilitates vesicular stomatitis virus oncolysisCancer Cell, 2004
- Selectively Receptor-Blind Measles Viruses: Identification of Residues Necessary for SLAM- or CD46-Induced Fusion and Their Localization on a New Hemagglutinin Structural ModelJournal of Virology, 2004
- VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agentsCancer Cell, 2003
- Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic ActivityJournal of Virology, 2003
- Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell markerBlood, 2003
- [The cellular receptor for measles virus: SLAM (CDw 150)].2000
- Vesicular Stomatitis Virus (VSV) Therapy of TumorsIUBMB Life, 2000